BRIEF published on 11/28/2024 at 18:45, 1 year 5 months ago Medincell annonce une vidéoconférence pour ses résultats semestriels Résultats Semestriels Schizophrénie Medincell Videoconference Technologie BEPO
BRIEF published on 11/28/2024 at 18:45, 1 year 5 months ago Medincell Announces Video Conference for Half-Year Results Half-year Results Schizophrenia Medincell Videoconference BEPO Technology
PRESS RELEASE published on 11/28/2024 at 18:40, 1 year 5 months ago Informations privilégiées / Autres communiqués Medincell tiendra une vidéoconférence pour présenter ses résultats financiers semestriels le mardi 10 décembre 2024. La société développe des médicaments injectables à action prolongée dans divers domaines thérapeutiques Résultats Financiers Medincell Médicaments Injectables Videoconference Technologie BEPO
BRIEF published on 11/22/2024 at 18:05, 1 year 5 months ago MedinCell : Mise à jour du capital social et des droits de vote Droits De Vote Euronext Capital Social Actions Medincell
BRIEF published on 11/22/2024 at 18:05, 1 year 5 months ago MedinCell: Update of share capital and voting rights Share Capital Voting Rights Euronext Actions Medincell
PRESS RELEASE published on 11/22/2024 at 18:00, 1 year 5 months ago Informations privilégiées / Autres communiqués Euronext informe sur les droits de vote et le capital social de MedinCell. MedinCell, biopharmaceutique en France, développe des médicaments injectables à action prolongée Droits De Vote Euronext Capital Social Biopharmaceutique Medincell
BRIEF published on 11/06/2024 at 13:47, 1 year 6 months ago Medincell : Revenus 2024 à la hausse et avancée clinique significative Clinical Trial Revenue Projections Medincell Olanzapine LAI UZEDY
BRIEF published on 11/06/2024 at 13:47, 1 year 6 months ago Medincell: 2024 revenues on the rise and significant clinical progress Clinical Trial Revenue Projections Medincell Olanzapine LAI UZEDY
PRESS RELEASE published on 11/06/2024 at 13:42, 1 year 6 months ago Informations privilégiées / Autres communiqués Medincell relève ses prévisions de revenus UZEDY® de 25% et franchit une étape majeure dans l'essai clinique de l'Olanzapine LAI. Tous les détails dans le communiqué de presse de Teva pour le troisième trimestre 2024 Revenus Essai Clinique Medincell Teva UZEDY
PRESS RELEASE published on 11/06/2024 at 13:42, 1 year 6 months ago Inside Information / Other news releases Medincell achieves 25% increase in 2024 UZEDY® revenue outlook reaching $100M and key milestone in Olanzapine LAI Phase 3 clinical trials. Teva Pharmaceuticals shares Q3 results Revenue Clinical Trials Medincell Teva Pharmaceuticals UZEDY
Published on 05/13/2026 at 00:00, 1 hour 25 minutes ago Onco-Innovations Announces Initiation of Research Collaboration within PROmAI
Published on 05/12/2026 at 23:35, 1 hour 50 minutes ago Infield Minerals Closes $1.25 Million Financing
Published on 05/12/2026 at 21:55, 3 hours 30 minutes ago UraniumX Discovery Corp Announces Option Agreement with Gold'n Futures
Published on 05/12/2026 at 21:42, 3 hours 43 minutes ago Kidoz Inc. to Present at Planet MicroCap Las Vegas 2026
Published on 05/12/2026 at 14:30, 10 hours 55 minutes ago Pathfinder Ventures Inc. Announces Conclusion of Financing and Intention to Launch New Private Placement
Published on 05/12/2026 at 23:47, 1 hour 37 minutes ago Nebius welcomes Clarifai’s core team and licenses inference IP to strengthen Nebius Token Factory
Published on 05/12/2026 at 22:25, 2 hours 59 minutes ago Evotec SE Successfully Placed €116.1 Million Convertible Bonds
Published on 05/12/2026 at 20:21, 5 hours 3 minutes ago Nebius breaks ground on gigawatt-scale AI factory in Independence, Missouri
Published on 05/12/2026 at 19:35, 5 hours 50 minutes ago AUSTRIACARD HOLDINGS AG: Q1 2026 Financial Results
Published on 05/12/2026 at 19:35, 5 hours 50 minutes ago 2026 Annual General Meeting: Strong vote by shareholders in favour of continuity in leadership and strategy
Published on 05/12/2026 at 18:15, 7 hours 10 minutes ago AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 30/04/2026
Published on 05/12/2026 at 18:15, 7 hours 10 minutes ago AXA: Information relating to the number of voting rights and shares making up the share capital on 30/04/2026
Published on 05/12/2026 at 18:10, 7 hours 15 minutes ago imerys-12-05-2026-communiqué-compte-rendu-de-l-assemblée-générale-ordinaire-du-12-mai-2026
Published on 05/12/2026 at 18:10, 7 hours 15 minutes ago imerys-12-05-2026-press-release-summary-of-the-ordinary-shareholders-general-meeting-12-may-2026
Published on 05/12/2026 at 17:50, 7 hours 35 minutes ago Damartex fait évoluer sa gouvernance et engage une réflexion stratégique autour de ses activités
